Thomson N M, Atkins R C, Scott D F, Marshall V C, McGinley E, Holdsworth S R, Ironside W
Med J Aust. 1983;2(12):609-12.
In a series of 271 transplantations of renal allografts, performed over 10 years, the rates of graft survival, patient survival, and morbidity in the recipients of allografts from living related donors (47 allografts) have been compared with those in the recipients of cadaveric allografts (224 allografts). The one-year graft survival rates were 88% for allografts from living related donors (100%, if these were HLA-identical) and 55% for cadaveric allografts, while the patient survival rates were 97% and 87%, respectively, in the same period. Morbidity rates (expressed as the number of days spent in hospital) for recipients of allografts from living related donors were approximately 50% of those for recipients of cadaveric grafts. Complications in the living related donors were minimal, and acceptable. It is concluded that transplantation of allografts from living related donors has many advantages over transplantation of cadaveric kidneys, and is a valuable adjunct to a cadaveric renal transplantation programme. Greater use of living related kidney donors should be encouraged in Australia.
在10年期间进行的271例同种异体肾移植系列手术中，对来自活体亲属供者的同种异体肾移植受者（47例）与尸体同种异体肾移植受者（224例）的移植物存活率、患者存活率和发病率进行了比较。来自活体亲属供者的同种异体肾移植1年移植物存活率为88%（若为HLA配型相同则为100%），尸体同种异体肾移植的1年移植物存活率为55%，同期患者存活率分别为97%和87%。来自活体亲属供者的同种异体肾移植受者的发病率（以住院天数表示）约为尸体肾移植受者的50%。活体亲属供者的并发症极少且可接受。得出的结论是，与尸体肾移植相比，活体亲属供者的同种异体肾移植有许多优势，是尸体肾移植计划的一项有价值的辅助手段。在澳大利亚应鼓励更多地使用活体亲属肾供者。
